Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer
Recruiting · NCT07531693 · Observational (researchers observe without assigning treatment) · Lead sponsor: Institut fuer Frauengesundheit
View the official record on ClinicalTrials.gov →What this trial is about
The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.
Who can take part
Age range
18 Years and older
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Femal patients age 18 or older at time of informed consent
- Confirmed diagnosis of HR+/HER2- early breast cancer (no distant metastasis)
- Prescribed abemaciclib therapy according to the Summary of Product Characteristics (SmPC)
- Abemaciclib therapy occured between January 1st, 2023 and June 30th, 2025
Exclusion criteria
- Locally advanced or metastatic breast cancer
- Male patients
- Patients with contraindication(s) for abemaciclib therapy according to SmPC
Where it is running
1 location listed.
- Department of Obstetrics and Gynaecology, Uniklinikum Erlangen - Erlangen, Bavaria, Germany